On Feb. 19, 2010, the U.S. Food and Drug Administration (FDA) announced it had licensed a quadrivalent meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics).

MenACWY-CRM was licensed as a single dose for use among persons aged 11–55 years. The Advisory Committee on Immunization Practices (ACIP) reviewed data from prelicensure clinical trials on the safety and immunogenicity of MenACWY-CRM.